Rétarutide

Description

Retatrutide is an investigational prescription medication developed by Eli Lilly, representing a next-generation triple receptor agonist that simultaneously activates glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors. It is being studied as an adjunct to diet and exercise for improving glycemic control in adults with type 2 diabetes mellitus and for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with weight-related conditions. By targeting three key incretin and metabolic pathways, Retatrutide enhances insulin secretion in a glucose-dependent manner, suppresses glucagon release, slows gastric emptying, reduces appetite, increases energy expenditure, and promotes fat oxidation—leading to potentially unprecedented improvements in blood sugar regulation and body weight reduction.

Phase 2 clinical trials (including the TRIUMPH program) have shown promising results: average A1C reductions of up to 2.0-2.5% from baseline and body weight losses exceeding 20-25% (often 50+ pounds or more over 48 weeks at higher doses), surpassing many dual GLP-1/GIP agonists like tirzepatide in preliminary data, while also demonstrating benefits in liver fat reduction, lipid profiles, and cardiometabolic health. Retatrutide is administered once weekly via subcutaneous injection using a pre-filled pen (typically in the abdomen, thigh, or upper arm), with gradual dose escalation starting at lower levels (e.g., 1mg or 2mg) and increasing every 4 weeks to minimize gastrointestinal side effects such as nausea, vomiting, diarrhea, constipation, abdominal pain, and decreased appetite, which are common but often transient during initiation and dose increases.

As of 2025, Retatrutide remains in late-stage clinical development (Phase 3 trials ongoing) and is not yet FDA-approved or available for commercial use—access is limited to clinical trial participants under strict medical oversight. Potential risks include thyroid C-cell tumors (observed in rodent studies, with a boxed warning anticipated upon approval), pancreatitis, gallbladder-related events, acute kidney injury, severe gastrointestinal issues, hypersensitivity reactions, and increased heart rate. It is not recommended during pregnancy, breastfeeding, or in patients with a personal/family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. If approved, Retatrutide could offer a powerful new option for patients with type 2 diabetes or obesity who have not achieved adequate results with existing therapies. Always consult a healthcare provider for the latest updates on clinical trial availability, potential future approval, and whether investigational treatments like Retatrutide may be suitable through research programs.